Hazelden.org

up-to-date, evidence-based treatment protocols Hazelden’s response to opioid dependence
We at Hazelden will support you every step
of the way. Our COR-12 programming offers
you the best opportunity for lifelong recovery.
Marvin D. Seppala, MD
Chief Medical Officer
Hazelden Foundation
hazelden.org/cor12
800-257-7800

We invite you to call us with questions. We are available 24 hours a day.
Comprehensive treatment services
Hazelden, a national nonprofit organization founded Hazelden offers innovative programming to in 1949, offers a comprehensive approach to addiction treat opioid addiction. Our Comprehensive that addresses the full range of patient, family and Opioid Response with Twelve Steps (COR-12) treatment program focuses on engaging you over professional needs, including treatment and continuing a longer period of time and encompasses family, care for youth and adults, research, higher education, support groups, accountability and the recovery public education and advocacy, and publishing.
When appropriate, two medications, buprenorphine with naloxone (Suboxone®) and extended-release naltrexone (Vivitrol®), will be available to provide stability while you are engaging in a Twelve Step-based recovery lifestyle.
In numerous controlled research studies, these Hazelden locations
medications have been shown to improve the likelihood of abstinence from opioids, boost retention and engagement in treatment, reduce cravings for opioids and lower relapse rates. CHICAGO, ILLINOIS MAPLE GROVE, MINNESOTA Avoiding relapse is critical to preventing overdoses and other consequences of opioid abuse and PLYMOUTH, MINNESOTA SPRINGBROOK, OREGON ST. PAUL, MINNESOTA hazelden.org/cor12
2013 Hazelden Foundation Hazelden and the Hazelden logo are registered trademarks of the Hazelden Foundation.
MAT-0680 4136-9 (10/13) Deciding which COR-12 pathway is right for you.
What do the COR-12 pathways look like?
At Hazelden, we know that treatment works and Opioid is an umbrella term for natural and synthetic painkillers, including many prescription pain pills and heroin. the pathway to lifelong recovery requires active Prolonged use of opioids fundamentally changes the brain and can make treatment and recovery even more challenging. To address these unique challenges, Hazelden offers you three possible COR-12 pathways, all of which involvement with Twelve Step-based recovery include enhanced treatment services: (1) the option of treatment without medications; (2) the use of buprenorphine/ naloxone; or (3) the use of extended-release naltrexone. Each of these three options results in better outcomes when a person actively engages in continuing care services.
For many individuals addicted to opioids, withdrawal and cravings can make it difficult to engage in treatment services All opioid-dependent patients who have significant withdrawal symptoms will initially be detoxed with buprenorphine/ and stay connected with essential support. When clinically naloxone (Suboxone®) in order to make this transition as comfortable as possible. Once your withdrawal is stabilized, appropriate, recovery may be assisted by certain medications your treatment team will recommend the most appropriate COR-12 pathway for you. that allow for longer term engagement in treatment.
All three of our COR-12 pathways include enhanced treatment and recovery services as well as professionally Medication Pathways
led programming matched to your individual needs. Our continuum provides access to all levels of care, including: Weeks 2–3
Short- and long-term residential care Day treatment Intensive outpatient Extended outpatient treatment Halfway house and structured sober living Our interdisciplinary team works closely with you, your family, and other significant people in your life to recommend the most appropriate pathway. These recommendations are based upon clinical factors, such as: History of opioid use Treatment and recovery history Co-occurring mental health issues In addition to comprehensive services, the three COR-12 options include: Recovery environment and support network 1. No Medication Pathway
On this pathway, your withdrawal will be medically treated, when clinically appropriate, with a gradual taper using Suboxone® over a one- to two-week period.
2. Buprenorphine/Naloxone Pathway
Buprenorphine/naloxone (Suboxone®) is a medication used to treat withdrawal and cravings while assisting your recovery
and allowing you to engage in supportive services over a longer period of time.
3. Extended-Release Naltrexone Pathway
Naltrexone is an “opioid receptor antagonist” and is administered as a monthly extended release injection. This medicine
blocks the effects of opioids and also helps with cravings so you can participate in treatment services.
We believe the combination of enhanced opioid
addiction treatment services, expanded use of
medication for opioid dependence, purposeful clinical
Medication-assisted treatment for opioid dependence with naltrexone and buprenorphine/naloxone is supported by scientific research and recommended by the U.S. Department of interventions and engagement over an extended period
Health and Human Services Substance Abuse and Mental Health Services Administration hazelden.org/cor12
of time offers the best opportunity for lifelong recovery.
(SAMHSA), the National Institute on Drug Abuse (NIDA), Washington Circle (a policy group devoted to improving care for substance use disorders) and the Veterans Administration.

Source: http://www.hazelden.org/web/public/document/cor-12-opioid-response.pdf

A_ircocervo_settembre10_layout

Le Coop rosse ed il boicottaggio verso Israele Il quotidiano Haarez (la versione israeliana del di Michela Mantovani Herald Tribune) lo scorso 23 maggio pubblica variarticoli, tra i quali spiccano i seguenti. La CoopItalia e la Nordiconad hanno annunciato che entrofine mese di maggio 2010 avrebbero boicottato tutti iprodotti agricoli provenienti da Israele distribuiti daCaramel-Agr

arterium.org.ua

The "Arterium" Corporation 01032, Kiev, Saksaganskogo Street, 139 Tel: (+380 44) 490 75 22 Fax: (+380 44) 490 75 17 Chief Executive Officer: Dennis Gartsylov The "Arterium" Corporation - one of the leading Ukrainian pharmaceutical companies, which operates in the industry that cares about the most important values - health and preservation of human life. Established in

Copyright © 2009-2018 Drugs Today